{"nctId":"NCT00775528","briefTitle":"Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis","startDateStruct":{"date":"2009-04"},"conditions":["Cystic Fibrosis","Pancreatic Exocrine Insufficiency"],"count":19,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Pancrelipase Delayed Release"]}],"interventions":[{"name":"Pancrelipase Delayed Release","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed Cystic Fibrosis (CF) diagnosis by two positive chloride sweat tests or gene analysis\n* Current or historical human fecal elastase \\< 50µg/gstool\n* Weight greater than 3.75 kg\n* Age 1 month to 6 years\n* Currently receiving treatment with a commercially available pancreatic enzyme product on a stable dose for more than 3 months\n* Clinically stable condition without evidence of acute respiratory disease or any other acute condition\n\nExclusion Criteria:\n\n* Ileus or acute abdomen\n* History of fibrosing colonopathy, Celiac disease, gastrectomy, Crohn´s disease and small bowel surgery other than minor resection due to meconium ileus without resulting in malabsorption syndrome\n* History of distal ileal obstruction syndrome within 6 months of enrollment\n* Use of an immunosuppressive drug\n* Any type of malignancy involving the digestive tract in the last 5 years\n* Known infection with HIV","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Month","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Stool Fat (% Fat)","description":"The stool fat content was calculated as percent fat of dry solid weight per bowel movement. Stool fat per patient was derived as mean over three bowel movements sampled (i.e. one sample per day).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.11","spread":"9.86"}]}]}]},{"type":"SECONDARY","title":"Fat Intake (g)","description":"The mean daily fat intake was determined as the average of daily fat intake over a 3-day period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.61","spread":"22.34"}]}]}]},{"type":"SECONDARY","title":"Total Calorie Intake (kcal)","description":"The total calorie intake was determined as the average of total calorie of daily food intake intake over a 3-day period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1239.71","spread":"605.78"}]}]}]},{"type":"PRIMARY","title":"Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE)","description":"Treatment Emergent Adverse Events are defined as adverse events started at or after the first administration of study drug and include those events started prior to the first administration but which worsened after the first intake.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Otitis media","Cough","Diarrhoea","Vomiting","Pyrexia"]}}}